Recruiting
Phase 2

RGX-314

Sponsor:

Sierra Eye Associates

Code:

NCT06942520

Conditions

Diabetic Macular Edema

Eligibility Criteria

Sex: All

Age: 25 - 70+

Healthy Volunteers: Not accepted

Interventions

RGX-314 Dose 1

RGX-314 Dose 2

Aflibercept (2.0 mg)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-27. This information was provided to ClinicalTrials.gov by Sierra Eye Associates on 2025-04-24.